Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Retained Earnings: 2023-2025

Historic Retained Earnings for Zenas BioPharma (ZBIO) over the last 1 years, with Sep 2025 value amounting to -$524.7 million.

  • Zenas BioPharma's Retained Earnings fell 56.72% to -$524.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$524.7 million, marking a year-over-year decrease of 56.72%. This contributed to the annual value of -$387.4 million for FY2024, which is 68.14% down from last year.
  • Per Zenas BioPharma's latest filing, its Retained Earnings stood at -$524.7 million for Q3 2025, which was down 10.88% from -$473.2 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Retained Earnings ranged from a high of -$230.4 million in Q4 2023 and a low of -$524.7 million during Q3 2025.
  • Over the past 3 years, Zenas BioPharma's median Retained Earnings value was -$404.2 million (recorded in 2024), while the average stood at -$395.2 million.
  • Data for Zenas BioPharma's Retained Earnings shows a maximum YoY tumbled of 68.14% (in 2024) over the last 5 years.
  • Zenas BioPharma's Retained Earnings (Quarterly) stood at -$230.4 million in 2023, then tumbled by 68.14% to -$387.4 million in 2024, then crashed by 56.72% to -$524.7 million in 2025.
  • Its Retained Earnings stands at -$524.7 million for Q3 2025, versus -$473.2 million for Q2 2025 and -$421.0 million for Q1 2025.